Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH4 in Peripheral Artery Disease
NCT03493412Phase 4Withdrawn
- Sponsor
- University of Nebraska
- Start
- Jul 2019
- Primary completion
- Jul 2019
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
01
Overview
Phase 4, randomised, double-blind trial of sapropterin in peripheral artery disease (PAD) (2 arms), sponsored by University of Nebraska. Primary endpoint: Endothelial Function at 2 days. Planned start Jul 2019; status: withdrawn.
02
Drugs
sapropterin
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT03493412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493412.